AIM ImmunoTech Announces Release of the Next CEO Corner Segment
25 Abril 2024 - 7:45AM
AIM ImmunoTech Inc. (NYSE American:
AIM) (“AIM” or the “Company”), today announced the
next CEO Corner segment has been published on the Company’s
website. For the CEO Corner segment, Thomas Equels, Chief Executive
Officer of AIM ImmunoTech, gave an overview of Metastatic
Pancreatic Cancer and the ongoing Phase 1b/2 clinical trial
combining AIM’s Ampligen® (rintatolimod) with AstraZeneca’s
anti-PD-L1 immune checkpoint inhibitor Imfinzi® (durvalumab) for
the treatment of late-stage pancreatic cancer (the “DURIPANC
Study”).
The CEO Corner segment is now available
here.
About AIM ImmunoTech Inc.
AIM ImmunoTech Inc. is an immuno-pharma company
focused on the research and development of therapeutics to treat
multiple types of cancers, immune disorders and viral diseases,
including COVID-19. The Company’s lead product is a first-in-class
investigational drug called Ampligen® (rintatolimod), a dsRNA and
highly selective TLR3 agonist immuno-modulator with broad spectrum
activity in clinical trials for globally important cancers, viral
diseases and disorders of the immune system.For more information,
please visit aimimmuno.com and connect with the Company
on X, LinkedIn, and Facebook.
Investor Contact:
JTC Team, LLC
Jenene Thomas
(833) 475-8247
AIM@jtcir.com
AIM ImmunoTech (AMEX:AIM)
Gráfica de Acción Histórica
De May 2024 a Jun 2024
AIM ImmunoTech (AMEX:AIM)
Gráfica de Acción Histórica
De Jun 2023 a Jun 2024